ScottAlanReinesMD

PubMed

• 1 citations
  IV tramadol: A novel option for US patients with acute pain-A review of its pharmacokinetics, abuse potential and clinical safety record
  Lucy Lu, Mark Harnett, Scott A Reines> ;Journal of Opioid Management. 2020 Jul 1
• 21 citations
  Misuse of Tramadol in the United States: An Analysis of the National Survey of Drug Use and Health 2002-2017.
  Scott A Reines, Bonnie Goldmann, Mark Harnett, Lucy Lu> ;Substance Abuse. 2020 Jun 3
• 6 citations
  Comparing the Pharmacokinetics of 2 Novel Intravenous Tramadol Dosing Regimens to Oral Tramadol: A Randomized 3-Arm Crossover Study.
  Lucy Lu, Michael Ryan, Mark Harnett, George Atiee, Scott A Reines> ;Clinical Pharmacology in Drug Development. 2020 May 1
• 11 citations
  Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients ...
  William A. Ball, Duane B. Snavely, Richard Hargreaves, Armin Szegedi, Christopher Lines, Scott A. Reines> ;Human Psychopharmacology. 2014 Nov 1
• 53 citations
  Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder.
  David Michelson, Richard Hargreaves, Robert C. Alexander, Paulette Ceesay, Jarmo Hietala, Christopher Lines, Scott A. Reines> ;The International Journal of Neuropsychopharmacology. 2013 Feb 1
• 21 citations
  Is bigger better for depression trials
  Kenneth Liu, Duane B. Snavely, William A. Ball, Christopher Lines, Scott A. Reines, William Z. Potter> ;Journal of Psychiatric Research. 2008 Jul 1
• 28 citations
  Rofecoxib in the Acute Treatment of Migraine: A Randomized Controlled Clinical Trial
  Joel Saper, Carl Dahlöf, Yuen T. So, Peer Tfelt-Hansen, William Malbecq, Thomas Loeys, Eleathea Barraclough, Meghan Klipfel, Christopher Lines, Hester Visser, Scott A....> ;Headache. 2006 Feb 1
• 211 citations
  Lack of Efficacy of the Substance P (Neurokinin1 Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder
  Martin B. Keller, Stuart Montgomery, William A. Ball, Mary Morrison, Duane B. Snavely, Guanghan Liu, Richard Hargreaves, Jarmo Hietala, Christopher R. Lines, Katherine...> ;Biological Psychiatry. 2006 Feb 1
• 357 citations
  A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.
  Leon J. Thal, Steven H. Ferris, Louis Kirby, G. Block, Christopher R. Lines, Eric C. Yuen, Christopher Assaid, Michael L. Nessly, Barbara A. Norman, Christine C Barana...> ;Neuropsychopharmacology. 2005 Jun 1
• Look-alike, sound-alike drug errors with Reminyl and Amaryl.
  Scott A. Reines> ;American Journal of Health-System Pharmacy. 2005 Jan 1
• 30 citations
  Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study.
  Jan Lewis Brandes, W. Hester Visser, Mildred V. Farmer, Amy L. Schuhl, William Malbecq, Christopher Lines, Scott A. Reines> ;Headache. 2004 Jun 1
• 134 citations
  Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant.
  Mats Bergström, Richard Hargreaves, H. Donald Burns, Michael R. Goldberg, David G. Sciberras, Scott A. Reines, Kevin J. Petty, Mattias Ögren, Gunnar Antoni, Bengt Lång...> ;Biological Psychiatry. 2004 May 15
• 198 citations
  Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression.
  Mark S. Kramer, Andrew Winokur, Jeffrey E. Kelsey, Sheldon H. Preskorn, Anthony J. Rothschild, Duane B. Snavely, Kalyan Ghosh, William A. Ball, Scott A. Reines, Dennis...> ;Neuropsychopharmacology. 2004 Feb 1
• 573 citations
  The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controll...
  Paul J. Hesketh, Steven M. Grunberg, Richard J. Gralla, D. G. Warr, Fausto Roila, Ronald de Wit, Sant P. Chawla, Alexandra D. Carides, Juliana Ianus, M. Elmer, Judith ...> ;Journal of Clinical Oncology. 2003 Nov 15
• 18 citations
  Pharmacokinetics of rizatriptan tablets during and between migraine attacks.
  Neal R. Cutler, Stanford S. Jhee, Anup K. Majumdar, Debra McLaughlin, Mary Jo Brucker, Alexandra D. Carides, Mark S. Kramer, Deborah Matzura-Wolfe, Scott A. Reines, Mi...> ;Headache. 1999 Apr 1
• 788 citations
  Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors
  Mark S. Kramer, N.R. Cutler, John P. Feighner, Ram K. Shrivastava, John Carman, John J. Sramek, Scott A. Reines, Guanghan Liu, Duane B. Snavely, Edwina Wyatt-Knowles, ...> ;Science. 1998 Sep 11
• 109 citations
  A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks
  Mark S. Kramer, Matzura-Wolfe D, Polis A, Getson A, Amaraneni Pg, Solbach Mp, McHugh W, J. Feighner, Silberstein S, Scott A. Reines> ;Neurology. 1998 Sep 1
• 139 citations
  The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia
  Mark S. Kramer, Albert Getson, Scott A. Reines> ;Archives of General Psychiatry. 1997 Jun 1
• 78 citations
  A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder
  Mark S. Kramer, N.R. Cutler, James C. Ballenger, William M. Patterson, Joseph Mendels, Alice Chenault, Ram K. Shrivastava, Deborah Matzura-Wolfe, Chris Lines, Scott A....> ;Biological Psychiatry. 1995 Apr 1
• 7 citations
  Pilot study of a CCKB antagonist in patients with panic disorder: preliminary findings.
  John J. Sramek, Mark S. Kramer, Scott A. Reines, N. R. Cutler> ;Anxiety. 1994 Jan 1
• 58 citations
  A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder
  Jacques Bradwejn, Diana Koszycki, Lawrence Annable, Anne Couëtoux du Tertre, Scott A. Reines, Chris Demetrios Karkanias> ;Biological Psychiatry. 1992 Nov 15
• Neurobiology of panic disorder.
  Karkanias CD, Block GA, Reines S, Bradwejn J> ;Am J Psychiatry. 1989-10-01
• Join now to see all